Hypha Labs Highlights Parallels Between Emerging Psychedelic Industry and Early Cannabis Market Expansion

State-Level Reform, Growing Public Acceptance, and Expanding Market Capitalizations Signal Potential Long-Term Industry Opportunity LAS VEGAS, NV / ACCESS Newswire / June 4, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company focused on scalable mushroom cultivation and active compound production technologies, today highlighted what it believes are significant parallels between the current psychedelic industry and the early stages of the legal cannabis market. Over the past decade, the cannabis industry evolved from a largely prohibited market into a multi-billion-dollar global sector driven by state-level legalization, growing public acceptance, expanding medical research, and increasing institutional investment.